Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

Background: We evaluated the erythropoietic effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes patients with anemia of chronic kidney disease. Methods: Nine diabetes patients were enrolled and administered 100 mg canagliflozin once a day for 12 weeks. The patien...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes Technol Ther
Main Authors: Maruyama, Takashi, Takashima, Hiroyuki, Oguma, Hidetaka, Nakamura, Yoshihiro, Ohno, Michiko, Utsunomiya, Kei, Furukawa, Tetsuya, Tei, Ritsukou, Abe, Masanori
Format: Artigo
Language:Inglês
Published: Mary Ann Liebert, Inc., publishers 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6875696/
https://ncbi.nlm.nih.gov/pubmed/31385724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2019.0212
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items